Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | RORA | P35398 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | RORB | Q92753 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27614118 | 0.91 | ENPP2 (0.50) | ENPP2PTGS2CA2RORCNR1I2 | |
| SCHEMBL6181168 | 0.83 | ENPP2 (0.43) | ENPP2PTGS2RORCNR1I2RORA | |
| SCHEMBL4949390 | 0.82 | ENPP2 (0.50) | ENPP2PTGS2CA2RORCNR1I2 | |
| SCHEMBL172035 | 0.79 | CA2 (0.64) | ENPP2PTGS2CA2PSIP1AKR1C3 | |
| SCHEMBL12309803 | 0.79 | CA2 (0.52) | CA2 | |
| SCHEMBL24188497 | 0.79 | TGM2 (0.40) | ENPP2PTGS2AKR1C3RORCNR1I2 | |
| SCHEMBL1500953 | 0.78 | ENPP2 (0.46) | ENPP2PTGS2RORCNR1I2RORA | |
| SCHEMBL2652094 | 0.78 | ENPP2 (0.52) | ENPP2PTGS2PSIP1AKR1C3RORC | |
| SCHEMBL5001127 | 0.78 | ENPP2 (0.46) | ENPP2PTGS2CA2RORCNR1I2 | |
| SCHEMBL4949383 | 0.78 | ENPP2 (0.46) | ENPP2PTGS2CA2RORCNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919353-B2 | Substituted 8-arylquinolune PDE4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2005-07-19 | — | — | US | disclosed |
| EP-1404330-B1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-06-01 | — | — | EP | disclosed |
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2004-08-19 | — | — | US | disclosed |
| EP-1404330-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003002118-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002118-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | PDE12, PDE4A, PDE4B | ENPP2 941/4885PTGS2 382/4885CA2 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.